Skip to main content
Premium Trial:

Request an Annual Quote

Merck KGaA Using Oncomethylome Test in Drug Studies

NEW YORK (GenomeWeb News) – OncoMethylome Sciences said today that it is collaborating with Merck KGaA to use its MGMT gene promoter methylation technology to select patients for trials for drugs to treat glioblastoma.

The Liege, Belgium-based company said it has begun testing for MGMT gene promoter methylation in a Phase II clinical trial for Merck KGaA's cilengitide and in a phase III clinical trial for newly diagnosed glioblastoma that has been ongoing since 2008, the company said.

The Phase III trial is attempting to demonstrate improvements in overall survival in patients with methylated MGMT gene promoter who are being treated with a combination therapy of cilengitide treatment along with temozolomide and radiation, which is the standard glioblastoma therapy.

In the Phase II trial, patients with unmethylated gene promoter are being enrolled and treated with an alternative cilengitide dosing schedule.

Under an earlier agreement, Merck KGaA acquired a non-exclusive, worldwide license to use the results of the MGMT methylation assay for glioblastoma treatment with cilengitide, for which the German company agreed to pay OncoMethylome fees for its testing services.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.